Background Information on Patients
| Category | No. | % |
|---|---|---|
| Age (y)* | ||
| All | 76 | 100 |
| >50 | 25 | 32.9 |
| 20–50 | 45 | 59.2 |
| <20 | 6 | 7.9 |
| Sex | ||
| Female | 61 | 80.3 |
| Male | 15 | 19.7 |
| Ethnicity | ||
| Caucasian | 63 | 82.9 |
| African American | 9 | 11.8 |
| Asian | 1 | 1.3 |
| Hispanic | 1 | 1.3 |
| Not stated | 2 | 2.6 |
| Smoking† | ||
| Yes | 8 | 10.5 |
| No | 68 | 89.5 |
| ATD‡ | ||
| Yes | 19 | 25.0 |
| No | 57 | 75.0 |
| TSI index | ||
| ≤1.8 | 14 | 18.4 |
| >1.8§ | 34 | 44.7 |
| All | 48 | 63.1 |
| FT3 (pmol/L)‖ | ||
| <16.6 | 31 | 40.8 |
| ≥16.6 | 28 | 36.8 |
| All | 59 | 77.6 |
↵* Age in years: mean, 42.9; SD, 14.8; range, 10.6–72; median, 44.
↵† Cigarette smoking during previous year or during study.
↵‡ Methimazole or propylthiouracil. Discontinued at least 3 d before 131I therapy.
↵§ Level considered positive and reflective of Graves' disease.
↵‖ Upper limit of normal, 8.3 pmol/L.